Apimeds Pharmaceuticals US, Inc. 8-K

What Happened
Apimeds Pharmaceuticals US, Inc. (APUS) filed an 8-K (dated July 13, 2026) to report that a majority of its stockholders approved, by written consent on December 1, 2025, a 1-for-10 reverse stock split and an amendment to its certificate of incorporation. The company states the waiting period has passed and it expects to file the charter amendment on or about July 23, 2026, with the Reverse Stock Split becoming effective at 12:01 a.m. Eastern Time on July 24, 2026. APUS expects its common stock to begin trading on a split-adjusted basis on the NYSE American under the symbol "APUS" at the open of trading on July 24, 2026.

Key Details

• Reverse split ratio: 1-for-10 (every 10 shares combined into 1 share).
• Written Consent approving split: December 1, 2025.
• Expected charter filing with Delaware Secretary of State: on or about July 23, 2026.
• Effective date/time: 12:01 a.m. ET on July 24, 2026; trading split-adjusted on NYSE American at market open that day.
• New CUSIP after split: 03771D201.
• The company previously expected an effective date of March 26, 2026 but did not file then; the waiting period required after mailing the definitive Information Statement has now passed.

Why It Matters
A reverse stock split reduces the number of outstanding shares and proportionally increases the per-share price; it does not change each shareholder’s percentage ownership except for possible rounding of fractional shares. For investors, the split will alter the share count, per-share basis and the stock’s CUSIP, and trading will reflect the new share ratio beginning July 24, 2026. The filing confirms the company’s procedural steps (stockholder consent, information statement, charter amendment filing) required to effect the split.